WAVE Life Sciences (WVE) to Release Quarterly Earnings on Wednesday

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) is expected to announce its Q2 2025 earnings results before the market opens on Wednesday, July 30th. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $11.52 million for the quarter.

WAVE Life Sciences (NASDAQ:WVE - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.02). The firm had revenue of $9.18 million during the quarter, compared to the consensus estimate of $11.65 million. During the same period last year, the firm earned ($0.24) EPS. On average, analysts expect WAVE Life Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

WAVE Life Sciences Trading Down 2.0%

Shares of NASDAQ WVE traded down $0.17 during mid-day trading on Thursday, hitting $8.39. The company had a trading volume of 1,001,552 shares, compared to its average volume of 1,284,076. The company has a market capitalization of $1.31 billion, a PE ratio of -9.99 and a beta of -1.01. The firm has a 50-day simple moving average of $6.93 and a two-hundred day simple moving average of $8.50. WAVE Life Sciences has a one year low of $5.04 and a one year high of $16.74.

Insider Activity

In other news, Director Gregory L. Verdine sold 30,000 shares of the company's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $6.95, for a total transaction of $208,500.00. Following the completion of the transaction, the director directly owned 282,517 shares in the company, valued at approximately $1,963,493.15. This represents a 9.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 23.98% of the company's stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in WAVE Life Sciences stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in WAVE Life Sciences Ltd. (NASDAQ:WVE - Free Report) by 9.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 57,349 shares of the company's stock after purchasing an additional 4,957 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in WAVE Life Sciences were worth $463,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 89.73% of the company's stock.

Analysts Set New Price Targets

WVE has been the subject of a number of research analyst reports. Wedbush restated an "outperform" rating and set a $18.00 price objective on shares of WAVE Life Sciences in a report on Monday, June 23rd. Raymond James Financial assumed coverage on shares of WAVE Life Sciences in a research report on Wednesday, June 11th. They issued an "outperform" rating and a $14.00 price target for the company. HC Wainwright reiterated a "buy" rating and issued a $22.00 price target on shares of WAVE Life Sciences in a research report on Wednesday, March 26th. Cantor Fitzgerald assumed coverage on shares of WAVE Life Sciences in a research report on Tuesday, April 29th. They issued an "overweight" rating and a $10.00 price target for the company. Finally, Citigroup assumed coverage on shares of WAVE Life Sciences in a research report on Wednesday, July 16th. They issued a "buy" rating and a $16.00 price target for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $20.15.

About WAVE Life Sciences

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.